Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares reached a new 52-week low on Friday. The stock traded as low as $16.38 and last traded at $16.3930, with a volume of 561 shares traded. The stock had previously closed at $16.61.
Analyst Upgrades and Downgrades
IMNM has been the topic of several analyst reports. Truist Financial lifted their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Stifel Nicolaus reduced their price target on shares of Immunome from $24.00 to $23.00 and set a “hold” rating for the company in a research report on Tuesday, November 10th. Alliance Global Partners assumed coverage on shares of Immunome in a research note on Monday, September 21st. They issued a “buy” rating and a $32.00 price objective for the company. William Blair started coverage on shares of Immunome in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Fourteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immunome has an average rating of “Moderate Buy” and a consensus price target of $33.85.
Read Our Latest Research Report on Immunome
Immunome Trading Up 0.1%
The stock has a fifty day simple moving average of $19.92 and a 200-day simple moving average of $22.07. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -6.26 and a beta of 2.68.
Immunome (NASDAQ:IMNM – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). Sell-side analysts forecast that Immunome, Inc. will post -2.64 earnings per share for the current fiscal year.
Insider Activity
In related news, insider Jack Higgins sold 13,200 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the completion of the transaction, the insider directly owned 65,050 shares in the company, valued at approximately $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company’s stock.
Institutional Investors Weigh In On Immunome
Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Immunome during the 2nd quarter worth about $186,588,000. Primecap Management Co. CA bought a new stake in Immunome in the second quarter valued at about $97,081,000. Bank of America Corp DE bought a new stake in Immunome in the second quarter valued at about $13,729,000. Parkman Healthcare Partners LLC acquired a new position in Immunome in the second quarter worth about $12,591,000. Finally, Wellington Management Group LLP raised its position in Immunome by 10.1% in the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock worth $110,404,000 after purchasing an additional 478,239 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.
Immunome Company Profile
Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.
Further Reading
- Five stocks we like better than Immunome
- Palo Alto Networks’ Q1 Beat Gives Its Stock Rally Another Reason to Run
- Airfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter Test
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
